SpeeDx

SpeeDx

SpeeDx

Molecular diagnostic tools support Resistance Guided Therapy. Detect infectious disease and antibiotic resistance markers for informed treatment decisions.
Type
B2b
Founded
2009
Raised
$15M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$15,000,000
Venture capital (Series B) - 2020
Northpond Ventures
Team Size
1–10
Employees
Location
Headquarters
$15,000,000 Venture capital (Series B)
FinSMEs

SpeeDx Raises Additional $15M in Series B Funding